Targeted uterine mRNA treatment boosts fertility outcomes in mice

Researchers have developed a new method for delivering therapeutic messenger RNA (mRNA) directly to the uterine lining, potentially offering a novel approach to treating infertility. The strategy, tested in mice, utilizes modified lipid nanoparticles (LNPs) – tiny capsules made of fatty molecules – to deliver the mRNA.

A Targeted Approach to Infertility

The research, published January 19 in Nature Nanotechnology and funded by the National Institutes of Health, focuses on improving embryo implantation. The team at Johns Hopkins Medicine, working within the Wilmer Eye Institute and Center for Nanomedicine, demonstrated that their technique could restore embryo attachment in a mouse model of endometrial injury.

The Challenge of Endometrial Receptivity

Conditions like endometriosis and Asherman syndrome can hinder embryo implantation, even with assisted reproductive technologies (ART) such as in vitro fertilization. According to Laura Ensign, Ph.D., principal investigator and Marcella E. Woll Professor of Ophthalmology at Johns Hopkins Medicine, patients facing these challenges currently have limited FDA-approved treatment options. “What we’re doing [with our study] is establishing a new standard of care for people to explore,” she stated.

Did You Know? The research team filed a patent application (PCT/US2025/043687) related to this study through The Johns Hopkins University.

How mRNA Delivery Works

mRNA therapies introduce molecular instructions to cells, prompting them to create specific proteins without altering the cell’s DNA. This technology underlies newer cancer treatments and the mRNA COVID-19 vaccines. A key challenge in mRNA therapeutics is ensuring sufficient delivery to the target site while minimizing potential toxicity.

Overcoming Delivery Hurdles

The researchers focused on delivering mRNA encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune protein believed to enhance embryo attachment by increasing endometrial thickness. Initial attempts using conventional LNPs resulted in toxicity to the liver and spleen due to off-target delivery. To address this, the team modified the LNPs with a peptide called RGD.

RGD attaches to integrins, proteins found on the endometrium during the “window of implantation” (WOI) – the period when the uterine lining is receptive to embryos. This modification ensured more precise targeting of the endometrium, enhancing the therapeutic benefits of GM-CSF and reducing side effects when administered during the WOI.

Expert Insight: The precision of targeted mRNA delivery represents a significant advancement. Previous attempts to use GM-CSF protein directly were limited by its short lifespan and potential for distribution to unintended areas of the body. This LNP approach appears to overcome those limitations, offering a more controlled and potentially safer therapeutic strategy.

Promising Results in Mice

Experiments showed that GM-CSF protein expression in the mouse endometrium remained elevated for up to 24 hours after LNP infusion – nearly threefold higher than with a recombinant GM-CSF protein infusion. Importantly, GM-CSF levels in the blood were sixtyfold lower in mice receiving the mRNA-LNP, suggesting a reduced risk of organ toxicity. In a mouse model mimicking endometrial injury, the tailored mRNA-LNP treatment restored embryo attachment to levels comparable to healthy mice, a 67% improvement over untreated mice.

What’s Next?

The researchers plan to explore using their LNP delivery system to test other cytokines, growth hormones, and molecules that could further improve fertility. They also believe this system could be applied to other endometrial disorders, such as endometriosis and endometrial cancer. While the human menstrual cycle differs from that of mice, the window of implantation is a comparable process, suggesting potential for translation to human studies.

Frequently Asked Questions

What is mRNA therapy?

mRNA therapies present cells with instructions to create proteins without changing the cell’s DNA. This approach is used in some cancer therapies and the mRNA COVID-19 vaccines.

What are lipid nanoparticles (LNPs)?

LNPs are small capsules made of fatty molecules used to protect and deliver mRNA to specific locations in the body.

What is the window of implantation (WOI)?

The WOI is a period when the uterine lining is receptive to embryos, and the researchers targeted their delivery system to coincide with this timeframe.

Could this research eventually lead to new, more effective treatments for infertility, offering hope to individuals struggling to conceive?